Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar

NCT04425382 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT04425382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04425382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar
Lead sponsor
Hamad Medical Corporation
Phase
Observational
Overall status
Completed
Start date
March 1, 2020
Completion date
September 30, 2020
Enrollment
400 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid, pneumonia